BioSpace News Archive

CereVasc, Inc. announced that data from clinical studies examining the use of its eShunt System to treat elderly patients with normal pressure hydrocephalus and patients with communicating hydrocephalus following treatment for a ruptured cerebral aneurysm, was recently presented at the Congress of Neurological Surgeons (CNS) Annual Meeting in Washington, DC.

Azenta, Inc. announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16.

Kyverna Therapeutics (“Kyverna”) and ElevateBio, LLC (“ElevateBio”) today announced a partnership to advance process development and manufacturing to produce industry-leading Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced encouraging preliminary safety, tolerability, pharmacokinetic and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO™ I study evaluating OTX-2002 in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC (MYC) gene.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced that it held an Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that its Board of Directors (the “Board”) has appointed Amir Boloor, Chair of the Company’s Board, as Interim Chief Executive Officer (“CEO”), effective immediately following the departure of Brian Pedlar.

NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors directly targeting muscle function within neuromuscular disorders, today announces that the first patient has been dosed in a Phase II clinical trial with the ClC-1 inhibitor NMD670 in patients impacted by spinal muscular atrophy (SMA).

In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network announced Oncolytics Biotech, Inc. as the recipient of its second annual PanCAN Therapeutic Accelerator Award.